TAYLOR SHEPARD: Open Payments
NPI 1689332496 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$237 in 12 payments from 6 companies in 2025. Trend: 2023 $137 · 2024 $377 · 2025 $237
Food & beverage: $237
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $79 |
| Bioventus LLC | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $44 |
| DePuy Synthes Sales Inc. | 2 | $31 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Smith+Nephew, Inc. | 1 | $20 |
Products named: NUCALA, DUROLANE, EUFLEXXA, Iovera, Pico 14, ORTHOVISC, MONOVISC.
Industry payments across TX — which companies pay providers there.
